Lyra Therapeutics Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
Good day, everybody. Thank you for joining us at the Bank of America annual healthcare conference being conducted virtually this year. My name is Jason Gerberry. I'm one of the biopharma analysts at BofA. And I'm pleased to be introducing our next company presenter, Lyra Therapeutics; and CEO, Maria Palasis, who has some slides that she's going to run through. So I'm going to hand the mic over to Maria. So Maria, it's all yours.
Great, thank you, Jason. It's great to be here. Thank you for the invitation. And I am going to start on slide number 3, investment summary.
So we, now, at Lyra Therapeutics have completed three clinical studies on LYR-210. Both of the products that are in development right now are targeting Chronic Rhinosinusitis. In the US, there is 14 million patients that have CRS, and globally, it's a large problem throughout the world.
In the US, there are no FDA approved medicines to treat the indication of CRS. And in fact, the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |